Tim Powell

Tim advises on critical IP issues, including supplementary protection certificates, orphan designations, and regulatory exclusivities for clients in life sciences and biotech seeking to remain competitive in European and UK-regulated markets.

He has managed bet-the-company litigation and complex cross-border licensing deals, leveraging his experience to protect trade secrets where patents may not apply. Tim also led one of the first reverse-payment settlement cases in Europe. He frequently advises on the antitrust implications of IP licensing, including fair, reasonable, and non-discriminatory (FRAND) terms.

Companies seek out Tim for his deep life sciences and biotech patent litigation, regulatory compliance, and cross-border strategy knowledge as IP laws evolve in the United Kingdom and European Union. His experience with complex, multijurisdictional disputes, combined with his strategic insights on leveraging regulatory exclusivities and managing antitrust risks, makes him an invaluable asset for clients seeking to safeguard innovation and optimize competitive advantage.

• Represented a leading manufacturer of generic pharmaceuticals in its long-running litigation concerning a well-known drug; plaintiff alleged that the client infringed its patent for new use by marketing a “skinny label” product aimed at the off-patent, non-pain market; Supreme Court held plaintiff’s patent to be invalid